v3.26.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Financial Information by Segment

Financial information by segment is as follows:

 

   Cell Therapy   BioBanking   Degenerative Disease  Total 
   Year Ended December 31, 2025 
   Cell Therapy   BioBanking   Degenerative Disease  Total 
Net revenues  $3,807   $5,432   $17,311  $26,550 
Cost of revenues (excluding amortization of acquired intangible assets)   —    859    19,215   20,074 
Direct expenses   13,194    1,371    12,922   27,487 
Segment contribution  $(9,387)  $3,202   $(14,826) $(21,011)
Other general and administrative expenses                 38,804 
Amortization                 1,493 
Loss from operations                $(61,308)
Other expenses                 (30,405)
Loss before income taxes                $(91,713)

 

  

Cell

Therapy

   BioBanking   Degenerative Disease    Total 
   Year Ended December 31, 2024 
  

Cell

Therapy

   BioBanking   Degenerative Disease   Total 
Net revenues  $688   $5,140   $48,392   $54,220 
Cost of revenues (excluding amortization of acquired intangible assets)   —    1,172    13,817    14,989 
Direct expenses   15,807    1,673    20,846    38,326 
Segment contribution  $(15,119)  $2,295   $13,729   $905 
Other general and administrative expenses                  37,703 
Indirect expenses                  1,560(a)
Loss from operations                 $(38,358)
Other expenses                  (19,534)
Loss before income taxes                 $(57,892)
(a) Components of indirect expenses                    
                     
Change in fair value of contingent consideration liability                 $(193)
Amortization                  1,753 
Total indirect expenses                 $1,560